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http://dx.doi.org/10.1016/j.jacl.2014.0BACKGROUND: Purified palmitoleic acid (16-1; omega-7) has shown lipid-lowering and anti-
inflammatory benefits in open label, epidemiologic, and animal studies.
OBJECTIVE: Our objective was to perform the first randomized controlled trial of purified palmito-
leic acid supplementation in humans.
METHODS: Adults with dyslipidemia and evidence of mild systemic inflammation (high-sensitivity
C-reactive protein [hs-CRP] between 2 and 5 mg/L) were randomly allocated to receive either
220.5 mg of cis-palmitoleic acid (n 5 30) or an identical capsule with placebo (1000 mg of medium
chain triglycerides, n 5 30) once per day for 30 days. Participants were asked to maintain their current
diet. Serum lipids and hs-CRP were drawn at baseline and study completion.
RESULTS: At 30 days, there were significant mean (95% confidence interval [CI]) reductions in
CRP (21.9 [22.3 to 21.4] mg/L), triglyceride (230.2 [240.2 to 225.3] mg/dL), and low-density
lipoprotein (LDL) (28.9 [212.0 to 25.8] mg/dL), and a significant increase in high-density lipopro-
tein (HDL) (2.4 [1.5, 3.3] mg/dL) in the intervention group compared with control. These changes
equated to 44%, 15%, and 8% reductions in CRP, triglyceride, and LDL respectively, and a 5% in-
crease in HDL compared with control.
CONCLUSIONS: Purified palmitoleic acid may be useful in the treatment of hypertriglyceridemia
with the beneficial added effects of decreasing LDL and hs-CRP and raising HDL. Further study is
needed to elucidate mechanisms and establish appropriate human doses.
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Fat metabolism and glucose homeostasis are highly
interconnected processes that contribute to the pathogenesis
of insulin resistance and type 2 diabetes.1 At the cellular
level, diet-derived fat enters the circulation and is taken up
by adipocytes, where it is metabolized through mitochon-
drial beta-oxidation or stored as triglyceride. Palmitoleic
acid, or palmitoleate (16:1, n-7), synthesized from the break-
down of triglyceride or de novo from surplus carbohydrate,
has recently been identified as a lipokine, an adipose tissue–
derived lipid hormone that acts on liver and muscle tissue.1,2
Epidemiological data suggest that circulating palmitoleate is
involved in insulin sensitivity, cholesterol metabolism, and
hemostasis, although the net cardiovascular effect may be
mixed: lower low-density lipoprotein cholesterol (LDL),
higher high-density lipoprotein cholesterol (HDL), lower
fibrinogen, but higher triglycerides and greater insulin resis-
tance, at least in men.3 De novo biosynthesis of palmitoleate
occurs in the liver as the liver converts excess carbohydrate
into fat for long-term storage, and adipose-derived pal-
mitoleate appears to suppress hepatic fatty acid synthesis,
suggesting that the endogenous source(s) of palmitoleate—
hepatic or adipose—may be the cause, or result, of reported
divergent cardiovascular effects.3
Dairy4,5 products are rich sources of trans-palmitoleate,
whereas macadamia nuts6–9 and certain fish10 may contain
the cis isomer. In epidemiologic studies, higher intake of
the trans isomer from dairy has been associated with lower
levels of inflammation and a lower risk of diabetes, but with
mixed relationships to serum lipids.4,5 In most,7–9 but not
all,6 studies, macadamia nuts are associated with more
favorable serum lipid profiles. Whether the divergent ef-
fects are due to the palmitoleate or other oils or nutrients
found in these foods remains uncertain. Animal studies
have shown beneficial effects of supplemental palmitoleate
alone on liver and plasma lipids.11,12 Ex vivo studies have
also demonstrated that palmitoleate induces beta-cell pro-
liferation and improves secretory function in both animals13
and humans.14
Our objective was to conduct the first randomized
controlled trial of purified palmitoleic acid supplementation
in humans. We hypothesized that supplementation would
improve serum lipids and decrease inflammation.Methods
Design
We conducted a 30-day parallel, double-blinded, ran-
domized, placebo-controlled study with 60 healthy par-
ticipants. The study was carried out at Xyrion Medical
Institute, a private clinic and research center in Ponce,
Puerto Rico, and approved by the Institutional Review
Board of Ponce School of Medicine in Ponce. Recruitment
began in June 2013, enrollment began in July 2013, and thestudy was completed in September 2013. A short 30-day
study period was chosen because the study was considered
a proof-of-concept study.
Participants
Adults aged 21 years or older with high-sensitivity
C-reactive protein (hs-CRP) values between 2 and 5 mg/L
who were willing to maintain a stable diet during the study
were recruited. Exclusion criteria included a body mass
index (equal to weight in kilograms divided by height in
meters squared) $45; recent weight change (at least 3 kg
from the first visit to the end of the qualifying period 2 weeks
later); nephrotic range proteinuria (at least 3 g/day); current
or prior malignancy; history of bariatric surgery; long-term
treatment ($6 months) with antihypertensive or antidiabetic
medications treatment; weight-loss drugs within the past
6 months; thyroid-stimulating hormone $1.5 times upper
limit of normal; alanine aminotransferase or aspartate
aminotransferase $3 times the upper limit of normal;
unexplained creatine kinase (CK) concentration 3 or more
times the upper limit of normal; or creatine kinase increase
from known muscle disease. After informed consent by a
research associate, a baseline questionnaire was admi-
nistered to collect data on age, gender, weight, current
prescription medications, foods favored during weekdays
and weekends, frequency of exercise, history of major
surgeries and major medical problems, and use of supple-
ments or vitamins in the past month. These metrics were not
collected again at follow-up. Blood pressure and heart rate
were determined by automated sphygmomanometer with
the patient sitting and resting quietly for 5 minutes. A
baseline fasting lipid profile, thyroid-stimulating hormone,
complete metabolic panel, and hs-CRP levels were obtained
for all participants. Participants received a $25 stipend for
travel during their participation in the study.
Sample size determination
Based on variance findings from a prior small unpub-
lished open label study, the sample size of 60 participants
was estimated to provide 80% power to detect a 20%
reduction in hs-CRP in the experimental group compared
with control.
Randomization and blinding
Sixty participants, stratified by gender, were randomly
allocated by computer-generated random numbers in a 1:1
ratio to either the intervention or placebo arm. Participants
and the principal investigator (L.M.) were blinded towhether
each participant received supplement or placebo.
Intervention
The experimental fat preparation used in this study was
52.5% cis-palmitoleic acid, as determined by independent
Table 1 Fatty acid profile of experimental and placebo
supplements*
Common name
Lipid
number
Experimental
supplement (%)
Placebo
supplement (%)
Caprylic C 8:0 54.61
Pelargonic C 9:0 0.12
Capric C 10:0 45.11
Lauric C 12:0 0.10
Myristic C 14:0 1.62
Pentadecanoic C 15:1 0.62
Palmitoleic C 16:1 52.50
Margaric C 17:0 10.12
Margaroleic C 17:1 9.80
Stearic C 18:0 5.63
Oleic C 18:1 4.99
Linoleic C 18:2 1.42
Linolenic C 18:3 1.46
Arachidic C 20:0 3.50
Other fatty acids 6.66 0.05
*Each experimental capsule contained 420 mg of oil and each pla-
cebo capsule contained 1000 mg of oil. Thus, 52.5% of palmitoleic acid
equals 220.5 mg of palmitoleic acid per capsule. All individual identi-
fied fatty acid constituents in experimental and placebo supplements
in quantities greater than 0.5% are shown.
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(Table 1). The supplemental fat was obtained by double
metabolically distilling anchovy oil after the removal of
omega-3s, including eicosapentaenoic acid and docosahex-
aenoic acid. Participants in the intervention (experimental)
group received capsules containing 220.5 mg of palmitoleic
acid. Those in the control group received identical capsules
with 1000 mg of medium chain triglycerides (MCT)
(Table 1). MCT was chosen as an inert control because it
would not affect participants’ levels of hs-CRP, LDL, or
HDL. The amount of MCT was chosen so that the capsules
were identical in size and appearance to the palmitoleic
acid capsules. All participants were instructed to take 1
capsule per day with meals. All capsules were sourced
from the same drug company and made to look as much
alike as possible. Neither physician nor study staff saw
the capsules, which were given to participants in sealed bot-
tles. Compliance in each study arm was assessed by collect-
ing bottles at the end of the study.
Outcomes and statistical analyses
After completion of the 30-day study period, fasting lipid
profiles and hs-CRP levels were measured. All blood draws
were carried out at a Clinical Laboratory Improvement
Amendments –certified laboratory in Ponce. All 30 partic-
ipants in each arm provided baseline and 30-day follow-up
data. The primary outcome was change in hs-CRP and the
secondary outcomes were changes in triglyceride (TG),
LDL, and HDL. The study protocol was written to in-
clude participants with hs-CRP between 3 and 10 mg/dL;however, before the recruitment began, it was decided to
change this to mild systemic inflammation with hs-CRP
between 2 and 5 mg/dL. There were no changes to the
protocol after initiation of recruitment.
Continuous variables were summarized using means and
standard deviations. P values for the differences between
intervention and control groups at baseline were deter-
mined by Wilcoxon rank sum test for weight given its
non-normal distribution, 2 sample t-tests for other contin-
uous variables, and chi-square test for gender. Treatment ef-
fect estimates were determined using analysis of covariance
models of the mean difference between within-group net
changes of hs-CRP and fasting lipids, adjusted for baseline
levels of each biomarker. Estimates of percent change were
determined by dividing the effect estimate by the mean
baseline value of each biomarker. Although none of the par-
ticipants reported any conscious diet or lifestyle changes
during the course of the study, detailed assessments of
diet and lifestyle habits were not taken and therefore could
not controlled for in the statistical models. In sensitivity
analyses, analysis of covariance models were constructed
adjusting for potential confounders of the effect of palmito-
leic acid on hs-CRP and fasting lipids, including baseline
weight, age, and gender. All tests were 2-sided with a
P value , .05 considered statistically significant.Results
Thirty participants were randomly allocated to interven-
tion, 30 to control, all participants received the intended
treatment, and all were analyzed for the primary outcome
(Fig. 1). All supplement and placebo bottles were returned
empty to study coordinator at study completion. Baseline
characteristics of participants are shown in Table 2. Partic-
ipants were 17-70 years of age (mean, 45 years) and 63%
were female. Intervention and control groups differed
slightly in baseline heart rate and systolic blood pressure,
but because these characteristics were not thought to influ-
ence response to the supplement or placebo, they were not
factored into the analyses of treatment effect. Baseline and
30-day lipid and inflammatory marker values are shown in
Table 3. Both groups were dyslipidemic (LDL $ 100) with
evidence of systemic inflammation (CRP $ 3). There were
no significant differences between groups in lipid or
inflammatory markers at baseline. At 30 days, there were
significant mean (95% confidence interval [CI]) reductions
in CRP (21.9 [22.3 to 21.4] mg/L), TG (230.2 [240.2 to
225.3] mg/dL), and LDL (28.9 [212.0 to 25.8] mg/dL),
and a significant increase in HDL (2.4 [1.5 to 3.3] mg/dL)
in the intervention group compared with control. These
changes equated to 44%, 15%, and 8% reductions in
CRP, TG, and LDL, respectively, and a 5% increase in
HDL compared with control.
In sensitivity analyses with additional adjustment for
baseline weight, age, and gender, the mean (95% CI) effect
estimates were similar to the models adjusted solely for
Figure 1 Study flow diagram.
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TG, 230.1 (241.1 to 219.1) mg/dL; LDL, 28.6 (211.8
to 25.38) mg/dL; and HDL, 2.4 (1.4 to 3.3) mg/dL.
Two to 3 participants in the intervention group devel-
oped gastrointestinal distress and 1 developed a headache
during the study period. There were no reported side effects
or adverse effects in the control group.Discussion
Diabetes and cardiovascular disease are leading causes
of death worldwide, and strategies to reduce risk factors
for their occurrence are needed. In the current study, we
demonstrate that supplementation with purified palmitoleic
acid in adults with dyslipidemia and systemic inflamma-
tion, 2 risk factors for cardiometabolic disease, leads toTable 2 Baseline characteristics of study participants*
All
(n 5 60)
Intervention
(n 5 30)
Control
(n 5 30) P value
Age (y) 45 (16) 45 (17) 45 (15) .99
Gender
(% female)
38 (63%) 19 (63%) 19 (63%) 1.00
Weight (lb) 192 (51) 179 (45) 204 (55) .08
Heart rate
(beats/min)
81 (8) 78 (6) 84 (8) ,.01
Blood pressure (mmHg)
Systolic 117 (8) 115 (8) 120 (9) .03
Diastolic 68 (6) 68 (7) 68 (6) .96
*Mean (standard deviation) provided for continuous variables and
n (%) for gender.improved serum lipids and decreased inflammation. These
findings build on a growing body of animal and epidemi-
ological evidence on the potential benefits of palmitoleate.
Human studies
In an early cross-sectional study, circulating palmito-
leate (oral glucose tolerance test F ratio 8.2, P 5 .005; eu-
glycemic hyperinsulinemic clamp F ratio 7.8, P 5 .007) but
not total free fatty acids (oral glucose tolerance test F ratio
0.6, P 5 .42; clamp: F ratio 0.7, P 5 .40) correlated posi-
tively with insulin sensitivity, independent of age, sex,
and adiposity.15 In that study, with a 1-standard deviation
increase in palmitoleate, the odds for being in the highest
vs the lowest tertile of change in insulin sensitivity was
2.35 (95% CI 1.16 to 5.35). Subsequent epidemiological
data suggested that circulating palmitoleate is involved in
insulin sensitivity, cholesterol metabolism, and hemostasis,
although the net cardiovascular effect may be mixed: lower
LDL, higher HDL, lower fibrinogen, but higher triglycer-
ides and greater insulin resistance, at least in men.3 In other
epidemiologic studies, higher intake of the trans isomer
from dairy has been associated with lower levels of inflam-
mation and a lower risk of diabetes, but mixed relationships
to serum lipids.4,5
In most,7-9 but not all,6 studies, macadamia nuts are asso-
ciated with more favorable serum lipid profiles, but investi-
gations to date have been small (1 study of 71 participants,
but typically fewer than 35 participants) and of short dura-
tion (3-4 weeks). Moreover, the dose of palmitoleate pro-
vided in these studies is difficult to ascertain given that
interventions have provided, for instance, whole nuts (eg,
20 or 40 to 90 g/day)8,9 or nut oil (eg, 62 g/day).6 Assuming
Table 3 Baseline and 30-day biomarker values among experimental and control groups*
Biomarker Intervention (n 5 30) Control (n 5 30) Effect estimate P value
C-reactive protein (mg/L)
Baseline 4.3 (0.2) 4.3 (0.1) .88
30 day 2.1 (0.2) 4.0 (0.2) ,.001
21.9 (22.3 to 21.4) ,.0001
Triglyceride (mg/dL)
Baseline 202.4 (11.9) 210.6 (11.0) .70
30 day 170.3 (9.6) 207.2 (10.7) .01
230.2 (240.2 to 225.3) ,.0001
Low-density lipoprotein cholesterol (mg/dL)
Baseline 114.1 (4.3) 119.6 (4.9) .41
30 days 105.8 (3.7) 119.2 (4.3) .02
28.9 (212.0 to 25.8) ,.0001
High-density lipoprotein cholesterol (mg/dL)
Baseline 45.7 (1.0) 43.3 (1.0) .10
30 days 47.1 (0.9) 42.7 (0.9) ,.001
2.4 (1.5, 3.3) ,.0001
*Means (standard errors of the mean) shown for baseline and 30-day values; effect estimate determined by analysis of covariance adjusted for base-
line levels of each biomarker (mean and 95% CI shown); P values for baseline, 30 days, and effect estimates values represent between-group differences.
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as 17% of total fat,16 prior interventions have provided study
participants between 2.5 and 11.5 g/day of palmitoleate,
levels far greater than those in the current study. Our dosing
was based on preliminary, open label, nonrandomized, hu-
man dose–ranging studies (unpublished).
Animal and in vitro studies
Animal studies have shown beneficial effects of supple-
mental palmitoleate on liver and plasma lipids.11,12 Cao
et al. used quantitative lipidemic analyses and mice deficient
in adipose tissue lipid chaperones aP2 and mal2 to identify
palmitoleate as an adipose tissue–derived lipid hormone that
strongly stimulates muscle insulin action and suppresses
hepatosteatosis.2 In another study, one of the first with exog-
enous administration of palmitoleate, KK-Ay mice (a model
for studies of obese type 2 diabetes with low insulin sensi-
tivity) were orally administered 300 mg/kg of palmitoleic
acid or 300 mg/kg of palmitic acid daily for 4 weeks.12 Pal-
mitoleic acid reduced body weight increase, ameliorated the
development of hyperglycemia and hypertriglyceridemia,
and improved insulin sensitivity. In addition, liver weight,
hepatic lipid accumulation, and hepatic triglyceride levels
were lower in the palmitoleic acid group compared with
the control (vehicle and palmitic acid) groups. Furthermore,
palmitoleic acid down-regulated messenger RNA expres-
sions of pro-inflammatory adipocytokine genes (tumor ne-
crosis factor-a and resistin) in white adipose tissue as well
as lipogenic genes (SREBP-1, FAS, and SCD-1) in liver.
In vitro studies have demonstrated that palmitoleate is
cytoprotective and mitogenic,17 inducing beta-cell prolifera-
tion and improving secretory function in animals13 and hu-
mans.14 After treatment of rat skeletal muscle cells withpalmitoleate, basal glucose uptake was enhanced approxi-
mately 2-fold and associated with a rise in glucose oxidation
and glycogen synthesis, neither of which could be attributed
to activation of signaling proteins normally modulated by
stimuli such as insulin, nutrients, or cell stress.18 The in-
crease in glucose uptake did involve an increase in the
plasma membrane abundance of GLUT1 and GLUT4. In
contrast, palmitate caused a substantial reduction in insulin
signaling and insulin-stimulated glucose transport, but was
unable to antagonize the increase in transport elicited by pal-
mitoleate. These findings suggest that saturated andmonoun-
saturated fats exert distinct effects on insulin signaling
and glucose uptake.18 Palmitoleate may also increase the
insulin-inducible GLUT4 receptor by activation of peroxi-
some proliferator–activated receptor-gamma, the trans-
cription factor strongly expressed in adipocytes. In fact,
palmitoleic acid at 1 mM has been shown to induce a tran-
scriptional activity that corresponds to half the therapeutic
levels of the diabetes drug, rosiglitazone.19
Study strengths and limitations
Strengths of the current study include the randomized
nature, blinding, placebo supplements matched in taste
and appearance to the experimental supplements, and
complete follow-up. Limitations include the small sample
size, short duration, and absence of testing of plasma
concentration of palmitoleic acid to assess baseline status
or compliance with the intervention. In addition, lifestyle
and dietary factors, which may impact serum lipids and
hs-CRP, were not evaluated in detail, and measures of
weight, foods favored during weekdays and weekends,
and frequency of exercise were not collected at follow-
up. However, given the randomized nature of the study,
Bernstein et al Purified palmitoleic acid, C-reactive protein, and serum lipids 617potential confounders are anticipated to be evenly distrib-
uted between study arms.Conclusion
In this randomized, double-blinded, placebo control-
led trial, purified palmitoleic acid exerted potent anti-
inflammatory and lipid-modulating effects compared with
placebo. These findings build on a growing body of in vitro,
animal, and human studies, demonstrating the importance of
palmitoleic acid to regulating metabolism. Thus, purified
palmitoleicmay be a therapeutic approach in helpingmaintain
lipid levels within a healthy range as well as improving
inflammatory markers in patients with mild dyslipidemia and
inflammation. Larger and longer term studies are needed to
confirm these findings.
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